ProfileGDS5678 / 1437865_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 84% 83% 88% 85% 85% 84% 83% 82% 82% 86% 82% 82% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9930783
GSM967853U87-EV human glioblastoma xenograft - Control 26.2717184
GSM967854U87-EV human glioblastoma xenograft - Control 36.0293283
GSM967855U87-EV human glioblastoma xenograft - Control 46.9574588
GSM967856U87-EV human glioblastoma xenograft - Control 56.3918685
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.1052785
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0599984
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0263383
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.9845482
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0469282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5244686
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0393682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.991482
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.3473185